REGULATORY

LDP Panels Approve Proposal to Promote Regulatory Harmonization, Improve Access in Asia

March 8, 2019

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Liberal Democratic Party’s (LDP) committees on March 7 roughly approved a draft proposal to promote regulatory harmonization in Asia in the fields of pharmaceuticals and medical devices, calling for public-private-academic collaborations to sketch out a grand design so as…

To read the full story

Japan Cabinet OKs Bill to Amend PMD Law
March 20, 2019
PMD Bill Clears LDP Review, Cabinet OK Slated for March 19
March 18, 2019

REGULATORY

ONODERA GT’s Parkinson’s Gene Therapy Gets Sakigake Tag
June 10, 2026
Cabinet Approves Immunization Act Revision to Cover Antibody Drugs
June 10, 2026
LDP Lawmakers Seek Routine HPV Vaccinations for Males by April 2027
June 10, 2026
MHLW Lifts Part of Approval Conditions for Takeda’s Vyvanse
June 9, 2026
Drug Makers Seek Govt Support for Immunoglobulin Plant Investments: LDP Hearing
June 9, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…